Skip to main content
. 2019 Jul 8;51(7):76. doi: 10.1038/s12276-019-0274-7

Fig. 2. BLI images of subcutaneous liver tumors (n = 5 per group).

Fig. 2

a HepG2-Red-fLuc and (b) SMMC-7721-fLuc cell-derived tumor-bearing mice on days 0, 6, 12, and 18 post-drug treatment. Changes in BLI signal intensity, tumor volume, and mouse body weight in mice bearing HepG2-Red-fLuc (c, e, g) and SMMC-7721-fLuc (d, f, h) cell xenograft tumors were evaluated. (*) P < 0.05, (**) P < 0.01, (***) P < 0.001 vs. the control group